Literature DB >> 2153226

Feline leukemia virus infection as a potentiating cofactor for the primary and secondary stages of experimentally induced feline immunodeficiency virus infection.

N C Pedersen1, M Torten, B Rideout, E Sparger, T Tonachini, P A Luciw, C Ackley, N Levy, J Yamamoto.   

Abstract

Preexistent feline leukemia virus (FeLV) infection greatly potentiated the severity of the transient primary and chronic secondary stages of feline immunodeficiency virus (FIV) infection. Of 10 FeLV-FIV carrier cats, 5 died of experimentally induced FIV infection, compared with 2 deaths in 10 cats infected only with FeLV and 1 death in 7 cats infected only with FIV. FIV-infected cats with preexistent FeLV infections developed severe depression, anorexia, fever, diarrhea, dehydration, weight loss, and leukopenia 4 to 6 weeks after infection and were moribund within 2 weeks of the onset of signs, whereas cats infected only with FIV developed much milder self-limiting gross and hematologic abnormalities. Pathologic findings in dually infected cats that died were similar to those observed previously in cats dying from uncomplicated primary FIV infection but were much more widespread and severe. Coinfection of asymptomatic FeLV carrier cats with FIV did not increase the levels of FeLV p27 antigen present in their blood over that seen in cats infected with FeLV alone. The amount of proviral FIV DNA was much higher, however, in dually infected cats than in cats infected only with FIV; there was a greater expression of FIV DNA in lymphoid tissues, where the genome was normally detected, and in nonlymphoid tissues, where FIV DNA was not usually found. Dually infedted cats that recovered from the primary stage of FIV infection remained more leukopenic than cats infected with FIV or FeLV alone, and their CD4+/CD8+ T-lymphocyte ratios were inverted. One of these cats developed what was considered to be an opportunistic infection. It was concluded, therefore, that a preexistent FeLV infection in some way enhanced the expression and spread of FIV in the body and increased the severity of both the resulting transient primary and chronic secondary stages of FIV infection. This study also demonstrated the usefulness of the FIV model in studying the role of incidental infectious diseases as cofactors for immunodeficiency-causing lentiviruses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153226      PMCID: PMC249149     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

Review 1.  Clinical aspects of HIV infection in developing countries.

Authors:  C P Conlon
Journal:  Br Med Bull       Date:  1988-01       Impact factor: 4.291

2.  Significance of viral co-infections by HIV, HTLV-1, Epstein-Barr virus and cytomegalovirus for immunological conditions in Japanese hemophiliacs.

Authors:  S Okubo; K Yasunaga
Journal:  AIDS       Date:  1988-08       Impact factor: 4.177

3.  Racial/ethnic differences in the risk of AIDS in the United States.

Authors:  R M Selik; K G Castro; M Pappaioanou
Journal:  Am J Public Health       Date:  1988-12       Impact factor: 9.308

4.  Characteristics of human herpesvirus-6.

Authors:  C Lopez; P Pellett; J Stewart; C Goldsmith; K Sanderlin; J Black; D Warfield; P Feorino
Journal:  J Infect Dis       Date:  1988-06       Impact factor: 5.226

5.  Clinical manifestations of AIDS in tropical countries.

Authors:  J W Carswell
Journal:  Trop Doct       Date:  1988-10       Impact factor: 0.731

6.  Effects of HIV superinfection on HBV replication in a chronic HBsAg carrier with liver disease.

Authors:  G Pastore; T Santantonio; L Monno; M Milella; N Luchena; G Angarano
Journal:  J Hepatol       Date:  1988-10       Impact factor: 25.083

Review 7.  Interactions of cytomegalovirus with the human immune system.

Authors:  A H Rook
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

Review 8.  Hematologic aspects of human immunodeficiency virus infection: laboratory and clinical considerations.

Authors:  L A Perkocha; G M Rodgers
Journal:  Am J Hematol       Date:  1988-10       Impact factor: 10.047

9.  Risk factors for the spread of AIDS in rural Africa: evidence from a comparative seroepidemiological survey of AIDS, hepatitis B and syphilis in southwestern Uganda.

Authors:  C P Hudson; A J Hennis; P Kataaha; G Lloyd; A T Moore; G M Sutehall; R Whetstone; T Wreghitt; A Karpas
Journal:  AIDS       Date:  1988-08       Impact factor: 4.177

10.  Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats.

Authors:  J K Yamamoto; E Sparger; E W Ho; P R Andersen; T P O'Connor; C P Mandell; L Lowenstine; R Munn; N C Pedersen
Journal:  Am J Vet Res       Date:  1988-08       Impact factor: 1.156

View more
  36 in total

1.  Dynamics of two feline retroviruses (FIV and FeLV) within one population of cats.

Authors:  F Courchamp; C Suppo; E Fromont; C Bouloux
Journal:  Proc Biol Sci       Date:  1997-06-22       Impact factor: 5.349

2.  Naturally acquired feline immunodeficiency virus (FIV) infection in cats from western Canada: Prevalence, disease associations, and survival analysis.

Authors:  Madhu Ravi; Gary A Wobeser; Susan M Taylor; Marion L Jackson
Journal:  Can Vet J       Date:  2010-03       Impact factor: 1.008

3.  Phylogenetic analysis of the long terminal repeat of feline immunodeficiency viruses from Japan, Argentina and Australia.

Authors:  H Yamada; T Miyazawa; K Tomonaga; Y Kawaguchi; K Maeda; M C Castellano; C Kai; Y Tohya; T Mikami
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

Review 4.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

5.  Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.

Authors:  K M Remington; B Chesebro; K Wehrly; N C Pedersen; T W North
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

7.  Processing of the glycoprotein of feline immunodeficiency virus: effect of inhibitors of glycosylation.

Authors:  E B Stephens; E Monck; K Reppas; E J Butfiloski
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

8.  Nucleotide sequences of Australian isolates of the feline immunodeficiency virus: comparison with other feline lentiviruses.

Authors:  W K Greene; J Meers; B Chadwick; P R Carnegie; W F Robinson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

9.  Epizootiology and management of feline leukemia virus in the Florida puma.

Authors:  Mark W Cunningham; Meredith A Brown; David B Shindle; Scott P Terrell; Kathleen A Hayes; Bambi C Ferree; R T McBride; Emmett L Blankenship; Deborah Jansen; Scott B Citino; Melody E Roelke; Richard A Kiltie; Jennifer L Troyer; Stephen J O'Brien
Journal:  J Wildl Dis       Date:  2008-07       Impact factor: 1.535

10.  Subclinical infection with avian influenza A (H5N1) virus in cats.

Authors:  Michael Leschnik; Joachim Weikel; Karin Möstl; Sandra Revilla-Fernández; Eveline Wodak; Zoltan Bagó; Elisabeth Vanek; Viviane Benetka; Michael Hess; Johann G Thalhammer
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.